New research appearing in the Journal of the National Comprehensive Cancer Network found that incorporating information from ...
At a per-patient level, 68 Ga-PSMA-11 identified 36% (18/50) of trial participants as having a positive scan, while 64 Cu-SAR-bisPSMA next-day imaging detected prostate cancer in 78% (39/50) of cases.
A new combination of drugs could help delay the advancement of a deadly form of prostate cancer in those with an advanced form of the disease, new research has found. The “striking” findings showed an ...
A new treatment strategy tested by UCLA researchers could offer new hope for men whose prostate cancer has returned after initial treatment. This approach could also help delay the need for hormone ...
Docetaxel rechallenge significantly improved survival compared with cabazitaxel in certain men with metastatic ...
Vipul R. Patel, MD, FACS, is a board-certified urologic surgeon, medical director of the Global Robotics Institute at AdventHealth, and medical director of urologic oncology at AdventHealth Cancer ...
A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, lowering the risk of death after eight years by 40.3%. What's more, the drug ...
Focal therapy now helping in the fight against prostate cancer With focal therapy, doctors are now able to destroy cancer cells without damaging the surrounding nerves and tissue. In today’s ...
The phase 2b study is an open-label trial that will enroll 40 men with advanced prostate cancer who are appropriate candidates for ADT. Participants will receive an initial loading dose of teverelix ...
St Bartholomew's Hospital and The James Cook University Hospital mark key UK expansion of the company's Phase 2 mCRPC programme Dr Kenrick Ng, Medical Oncology Consultant, St Bartholomew's Hospital, ...
Researchers have discovered that prostate cancer depends on two key enzymes, PDIA1 and PDIA5, to survive and resist therapy. When blocked, these enzymes cause the androgen receptor to collapse, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results